Immatics IMTX
$5.77 −$0.18 (-3.03%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $5.88 +1.91%
Open$5.86
Prev close$5.95
Day range$5.72 – $5.95
Volume746.7K
Market cap$878.58M
P/E (TTM)–
Dividend yield–
IMTX Stock News
Headlines matching Immatics or the IMTX ticker, most recent first.
- Jefferies Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $17 Negative
- Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $25
- TD Cowen Maintains Immatics(IMTX.US) With Buy Rating
- Goldman Sachs Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $11.8 Negative
- BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $17
- Earnings Flash (IMTX) Immatics Posts Q2 Revenue 9.1M Euros, Vs. FactSet Est of 10.4M Euros
- Chardan Capital Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $25
- Goldman Sachs Maintains Immatics(IMTX.US) With Buy Rating, Raises Target Price to $12.2 Positive
- Guggenheim Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $19
- TD Cowen Initiates Immatics(IMTX.US) With Buy Rating
- Leerink Partners Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $17
- Analysts Conflicted on These Healthcare Names: Siemens Healthineers AG (OtherSEMHF), Immatics (IMTX) and Aardvark Therapeutics, Inc. (AARD)
- Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD), Immatics (IMTX) and BrightSpring Health Services, Inc. (BTSG)
- Jefferies Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $18
- Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $25
No comments yet — be the first to weigh in on IMTX.
Sign in to join the discussion.